Aviptadil
Aviptadil is an injectable synthetic formulation of human vasoactive intestinal peptide (VIP). VIP was discovered in 1970, and has been used to treat various inflammatory conditions, such as acute respiratory distress syndrome (ARDS), asthma, and chronic obstructive pulmonary disease (COPD). Regulatory history ARDS in COVID-19 Studies have found that aviptadil may be beneficial for severely ill patients with COVID-19 related ARDS. ACTIV-3, a trial examining aviptadil acetate (Zyesami), is recruiting patients . A separate trial is examining inhaled aviptadil for patients with high risk for ARDS, is ongoing . A trial for intravenous aviptadil for the same indication concluded in February 2021. US-Israeli NeuroRx Inc partnered with Relief Therapeutics to develop aviptadil in the United States. In June 2020, the U.S. Food and Drug Administration granted fast-track designation to aviptadil for the treatment of respiratory distress in COVID-19. In September 2020, NeuroRX submitted a request for an Emergency Use Authorization to the US FDA for its use in patients in intensive care. Jan 2021: Zuventus healthcare Ltd seeks approval for aviptadil from India's drug controller for emergency use in COVID-19 treatment. Mumbai's Zuventus Healthcare Ltd. has got the nod to conduct Phase 3 clinical trials of aviptadil injectable formulation. The